#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Squamous cell carcinoma of head and neck Fallopian tube cancer Neovascular age-related macular degeneration Hereditary hypophosphataemic rickets Brain injury Heavy menstrual bleeding Infection in an immunocompromised host Soft tissue necrosis Acute hepatic failure Thalassaemia Epstein-Barr virus infection Mitochondrial DNA depletion Systemic lupus erythematosus Inborn error of metabolism Leukocyte adhesion deficiency type I More trials…

    Learn about Rare Diseases

    Prolymphocytic leukaemia – Life with Disease Breast angiosarcoma – Trials in Disease Congenital generalised lipodystrophy – Diagnostics Niemann-Pick disease Atypical haemolytic uraemic syndrome – Diagnostics Mucopolysaccharidosis II – Diagnostics Ocular melanoma – Treatment Malignant fibrous histiocytoma – Treatment Waldenstrom’s macroglobulinaemia refractory – Life with Disease KBG syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Streptococcus Agalactiae CAMOSTAT MESILATE Tyra-300-B01 Fidanacogene Elaparvovec Thiamazole Asp1570 Pantoprazole Gs-5718-03 Inupadenant Ibrutinib OMTX705 Delafloxacin Dobutamine Ertapenem Sodium Oxybate Tng462 Colecalciferol Brentuximab Vedotin Tiragolumab Ly3437943 Sodium More therapies…

    Learn about Your Condition

    Erythema multiforme Neuromyopathy Hyperkalaemia Sjogren's syndrome Glomerulonephritis acute Erdheim-Chester disease Endometrial cancer recurrent Caesarean section Paraganglion neoplasm Brain neoplasm Hypertension Muscle injury Huntington's disease Angiosarcoma non-metastatic Post procedural infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. ICMR (International Center for Medical Research)

ICMR (International Center for Medical Research)

Calle De Cinca 21, Madrid, 28002, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • A study testing BFB759 compared to placebo to evaluate effectiveness and safety in adult patients with atopic dermatitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia Germany Poland Spain

  • Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sonelokimab
    Belgium Bulgaria Czechia France Germany Hungary +7

  • Study on the Effects of Ritlecitinib in Patients Aged 12 and Older with Alopecia Areata

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Alopecia areata
    Czechia Poland Spain

  • Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Clindamycin Hydrochloride
    • SALICYLIC ACID
    • Remibrutinib
    Austria Belgium Czechia France Germany Greece +4

  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Austria Belgium Denmark Germany Hungary Poland +2

  • Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Dupilumab
    Germany Poland Spain

  • Study on the Safety and Effectiveness of APG777 for Patients with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Apg777
    Czechia France Germany Hungary Poland Spain

  • Study on the Effects of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Sonelokimab
    Belgium Bulgaria Czechia France Germany Ireland +4

  • Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

    Not recruiting

    3 1
    Investigated Drugs:
    • Upadacitinib
    Belgium Bulgaria France Germany Hungary Italy +5

  • Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-81241459
    France Germany Poland Spain
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!